Cargando…
Tumour mutational burden: primary versus metastatic tissue creates systematic bias
Tumour mutational burden (TMB) has emerged as a reproducible biomarker to predict immunotherapy response across multiple cancer types. However, a key aspect of TMB measurement that is often overlooked is the source of tissue sample used, which creates a potential for systematic bias. The predominant...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9216665/ https://www.ncbi.nlm.nih.gov/pubmed/35755001 http://dx.doi.org/10.1016/j.iotech.2019.11.003 |